Error loading player: No playable sources found

CAN2214

Due Diligence and Transaction Readiness

Date
August 9, 2022
$49
Standard Price
This product is also available as part of the following products:
Thumbnail for 2022 AICPA & CIMA Agriculture & Cannabis Industry Conference
This includes sessions from the conference: 2022 AICPA & CIMA Agriculture & Cannabis Industry Conference

The next lifecycle of a cannabis business often includes getting ready for the inevitable transaction. With M&A activity on the rise, learn from those who perform both buy-side and sell-side due diligence and how preparing your business for a sale helps on both sides of the transaction

Learning Objectives

  • Identify due diligence concerns and transaction readiness
  • Understand the legal and accounting framework to prepare for an exit

Speakers

Speaker Image for Christopher McLane
Director, Citrin Cooperman
Speaker Image for Elena Mervine
Managing Director, CohnReznick LLP
Speaker Image for Lauren Rudick
Partner, Hiller, PC

Session Categories

Related Products

Thumbnail for Cannabis Banking
Cannabis Banking
Cannabis businesses face unique challenges in obtaining typical financial services available to other industries. Hear from a series of providers to the industry and the unique nature of these aspects as they relate to the cannabis industry…
Thumbnail for Raising Capital in Cannabis
Raising Capital in Cannabis
Understand the funding options available to cannabis companies and typical methods of raising start-up capital
Thumbnail for Bankruptcy, Restructuring, and M&A Transactions Oh My!
Bankruptcy, Restructuring, and M&A Transactions Oh My!
Sometimes you win, sometimes you lose. Understand your options as cannabis businesses reach certain milestones or lifestages and understand the professionals who can help guide you through these critical steps…
Thumbnail for Cannabis Auditing and Financial Statements
Cannabis Auditing and Financial Statements
This session will focus on the unique aspects of cannabis auditing and financial statements including the frequent use of IFRS, including biological assets; challenges around valuations; income and cannabis tax exposure; inventory costing and other considerations…

This site uses cookies to store information on your computer. Some are essential to make our site work, others help us improve, the user experience. By using the site, you consent to the placement of these cookies. Visit our Privacy Center to learn more.